Background And Aim: To obtain diagnostic performance of diffusion-weighted magnetic resonance imaging (DWI) and fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the detection of pancreatic malignancy.
Methods: We performed a meta-analysis of all available studies of the diagnostic performance of DWI and PET/CT for pancreatic malignancy. MEDLINE, EMBASE, Cochrane library and some other databases were searched for initial studies. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves (SROC) using hierarchical regression models.
Results: Across 16 studies with 804 patients, PET/CT sensitivity was 0.87 (95% confidence interval [CI], 0.82, 0.81) and specificity was 0.83 (95% CI, 0.71, 0.91). Overall, LR+ was 5.84 (95% CI, 4.59, 7.42) and LR- was 0.24 (95% CI, 0.17, 0.33). DWI sensitivity was 0.85 (95% CI, 0.74, 0.92) and specificity was 0.91 (95% CI, 0.71, 0.98). LR+ was 9.53 (95% CI, 2.41, 37.65) and LR- was 0.17 (95% CI, 0.09, 0.32). In subgroup analysis, the sensitivity of enhanced versus unenhanced PET/CT in the detection of pancreatic cancer was 0.91 (95% CI, 0.86, 0.96) versus 0.84 (95% CI, 0.78, 0.90) (P > 0.05), the specificity 0.88 (95% CI, 0.73, 1.00) versus 0.81 (95% CI, 0.69, 0.94) (P > 0.05).
Conclusion: Positron emission tomography/computed tomography (PET/CT) was highly sensitive and DWI was a highly specific modality in diagnosing patients with pancreatic malignancy. PET/CT and DWI could play different roles in diagnosing pancreatic carcinoma. Enhanced PET/CT seems to be superior to unenhanced PET/CT. Further larger prospective studies are needed to establish its value for diagnosis in pancreatic cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1440-1746.2012.07112.x | DOI Listing |
Ann Nucl Med
January 2025
Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.
Dynamic positron emission tomography (PET) can be used to non-invasively estimate the blood flow of different organs via compartmental modeling. Out of different PET tracers, water labeled with the radioactive O isotope of oxygen (half-life of 2.04 min) is freely diffusable, and therefore, very well-suited for blood flow quantification.
View Article and Find Full Text PDFEJNMMI Phys
January 2025
Department of Nuclear Medicine, Rambam Health Care Campus, P.O.B. 9602, 3109601, Haifa, Israel.
Background: A recently released digital solid-state positron emission tomography/x-ray CT (PET/CT) scanner with bismuth germanate (BGO) scintillators provides an artificial intelligence (AI) based system for automatic patient positioning. The efficacy of this digital-BGO system in patient placement at the isocenter and its impact on image quality and radiation exposure was evaluated.
Method: The digital-BGO PET/CT with AI-based auto-positioning was compared (χ, Mann-Whitney tests) to a solid-state lutetium-yttrium oxyorthosilicate (digital-LYSO) PET/CT with manual patient positioning (n = 432 and 343 studies each, respectively), with results split into groups before and after the date of a recalibration of the digital-BGO auto-positioning camera.
ChemistryOpen
January 2025
Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, CAMH, Department of Psychiatry, University of Toronto, 250 College Street, Toronto, ON, M5T 1R8, Canada.
Tributyl(ethyl)phosphonium oxopentenolate ([P][Pen]) is an ionic liquid developed to capture CO and has shown ability to catalyze carbonylation reactions in organic chemistry. Carbon-11 (C, t=20.4 min) labeled CO is a highly versatile building block for the synthesis of positron emission tomography (PET) radiotracers that are applied for medical imaging.
View Article and Find Full Text PDFTransl Lung Cancer Res
December 2024
School of Medicine, Southeast University, Nanjing, China.
Background: Resistance to chemoimmunotherapy in patients with advanced non-small cell lung cancer (NSCLC) necessitates effective prognostic biomarkers. Although F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has shown potential for efficacy assessment, it has been mainly evaluated in immuno-monotherapy setting, lacking elaborations in the scenarios of immunotherapy combined with chemotherapy. To tackle this dilemma, we aimed to build a non-invasive PET/CT-based model for stratifying tumor heterogeneity and predicting survival in advanced NSCLC patients undergoing chemoimmunotherapy.
View Article and Find Full Text PDFTransl Lung Cancer Res
December 2024
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Preoperative assessment of lymph node status is critical in managing lung cancer, as it directly impacts the surgical approach and treatment planning. However, in clinical stage I lung adenocarcinoma (LUAD), determining lymph node metastasis (LNM) is often challenging due to the limited sensitivity of conventional imaging modalities, such as computed tomography (CT) and positron emission tomography/CT (PET/CT). This study aimed to establish an effective radiomics prediction model using multicenter data for early assessment of LNM risk in patients with clinical stage I LUAD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!